(24/7 MARKET NEWS) – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is popping, price and volume, after reporting positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma, this morning.
Transcode is trading at $1.43, 34 cents higher (+31.19%), on over 9 million shares.
Its 52-week range is $ 0.98 to $3.46, with this morning’s high of $1.59 looking like the next key inflection point, if it can break through that resistance, it can begin to challenge resistance points at the $1.75 and $2.00 levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
